Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Haim

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Journal of Medical Economics|April 16, 2019
Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment responseRegina Grebla, Juliana Setyawan, Chanhyun Park, et al.
Journal of Medical Economics|October 1, 2010
Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective studyAndrew P Yu, Jipan Xie, Arielle Bensimon, et al.
The Annals of Pharmacotherapy|March 19, 2011
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorderEric Q Wu, Andrew P Yu, Veronique Lauzon, et al.
Applied Health Economics and Health Policy|April 18, 2013
Authors' reply to Alatorre et al.: "cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison"M Haim Erder, Jipan Xie, James E Signorovitch, et al.
Journal of Medical Economics|June 23, 2011
Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costsAndrew P Yu, Rym Ben-Hamadi, Eric Q Wu, et al.
Applied Health Economics and Health Policy|November 2, 2012
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparisonM Haim Erder, Jipan Xie, James E Signorovitch, et al.
Journal of the American Medical Directors Association|October 30, 2010
Memantine discontinuation and the health status of nursing home residents with Alzheimer's diseaseHoward Fillit, Robert K Hofbauer, Juliana Setyawan, et al.
Mechanisms of Ageing and Development|April 21, 2010
Aberrant heterodimerization of keratin 16 with keratin 6A in HaCaT keratinocytes results in diminished cellular migrationA Trost, P Desch, V Wally, et al.
CNS Drugs|August 27, 2013
Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodologyVanja Sikirica, Robert L Findling, James Signorovitch, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchJames E Signorovitch, Vanja Sikirica, M Haim Erder, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Journal of Medical Economics|April 16, 2019
Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment responseRegina Grebla, Juliana Setyawan, Chanhyun Park, et al.
Journal of Medical Economics|October 1, 2010
Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective studyAndrew P Yu, Jipan Xie, Arielle Bensimon, et al.
The Annals of Pharmacotherapy|March 19, 2011
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorderEric Q Wu, Andrew P Yu, Veronique Lauzon, et al.
Applied Health Economics and Health Policy|April 18, 2013
Authors' reply to Alatorre et al.: "cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison"M Haim Erder, Jipan Xie, James E Signorovitch, et al.
Journal of Medical Economics|June 23, 2011
Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costsAndrew P Yu, Rym Ben-Hamadi, Eric Q Wu, et al.
Applied Health Economics and Health Policy|November 2, 2012
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparisonM Haim Erder, Jipan Xie, James E Signorovitch, et al.
Journal of the American Medical Directors Association|October 30, 2010
Memantine discontinuation and the health status of nursing home residents with Alzheimer's diseaseHoward Fillit, Robert K Hofbauer, Juliana Setyawan, et al.
Mechanisms of Ageing and Development|April 21, 2010
Aberrant heterodimerization of keratin 16 with keratin 6A in HaCaT keratinocytes results in diminished cellular migrationA Trost, P Desch, V Wally, et al.
CNS Drugs|August 27, 2013
Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodologyVanja Sikirica, Robert L Findling, James Signorovitch, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchJames E Signorovitch, Vanja Sikirica, M Haim Erder, et al.
Pageof 12